Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma [Phase 2]
Phase II study evaluating zanubrutinib with lenalidomide and R-CHOP as first-line therapy for diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-03-07Clinical Trial Update: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL [Phase 2]
Phase 2 trial investigating penpulimab with R2-GemOx regimen for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients [Phase 2]
Phase 2 trial comparing R-CHOP14 vs R-CHOP21 with consolidation PET-oriented radiotherapy in diffuse large B-cell lymphoma (DLBCL) has compl…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) [Phase 1]
Phase 1 study evaluating the safety and preliminary efficacy of the combination of blinatumomab and pembrolizumab in adults with relapsed or…
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL [Phase 2]
A Phase 2 trial evaluating the combination of obinutuzumab and venetoclax in relapsed or refractory diffuse large B-cell lymphoma has comple…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ibrutinib with lenalidomide and rituximab in relapsed or refractory diffuse large B-cell lymphoma has completed w…
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma [Phase 2]
Phase 2 protocol update for DLCL002 in high-risk aggressive B-cell lymphoma patients.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. [Phase 3]
Phase 3 trial comparing Zevalin regimen versus no further treatment in diffuse large B-cell lymphoma was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL [Phase 2]
Phase II clinical trial investigating the efficacy and safety of F520 in combination with F007 for relapsed/refractory diffuse large B-cell …
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects [Phase 2]
Phase 2 clinical trial update evaluating Chi-BEAC with auto-HSCT for aggressive lymphomas, reporting on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2021-12-27Clinical Trial Update: Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients [Phase 2]
Phase 2 trial update evaluating ofatumumab with IVAC salvage chemotherapy in patients with diffuse large B cell lymphoma (DLBCL) that has re…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 clinical trial update investigating zanubrutinib with rituximab and/or combination chemotherapy for newly diagnosed aggressive B-cel…
-
CLINICAL_TRIALS trial_result · 2021-12-16Clinical Trial Update: Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy [Phase 3]
Phase 3 trial evaluating Zevalin vs observation in older patients with newly diagnosed DLBCL achieving PET-negative complete remission after…
-
CLINICAL_TRIALS trial_result · 2021-12-09Clinical Trial Update: A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity [Phase 2]
Phase 2 safety and efficacy study of Defibrotide for preventing CAR-T cell–associated neurotoxicity in patients with DLBCL; study TERMINATED…
-
CLINICAL_TRIALS trial_result · 2021-12-08Clinical Trial Update: Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating a combination of chemotherapy, rituximab, and ixazomib citrate in adults with various aggressive B-cell lymphomas…
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
CLINICAL_TRIALS trial_result · 2021-11-23Clinical Trial Update: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This document reports the completion of a Phase 1/2 trial evaluating axicabtagene ciloleucel (KTE-C19) for adults with refractory or relapse…
-
CLINICAL_TRIALS trial_result · 2021-11-22Clinical Trial Update: PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT [Phase 3]
Phase 3 trial evaluating maintenance therapy with the PD-1 inhibitor tislelizumab in newly diagnosed diffuse large B-cell lymphoma patients …
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant [Phase 3]
Phase 3 trial comparing pixantrone + rituximab versus gemcitabine + rituximab in aggressive B-cell non-Hodgkin lymphoma and follicular grade…
-
CLINICAL_TRIALS trial_result · 2021-11-17Clinical Trial Update: Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial evaluating rituximab plus CHOP with sargramostim in newly diagnosed diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-11-08Clinical Trial Update: Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating zanubrutinib in participants with relapsed/refractory non-GCB type diffuse large B-cell lymphoma has completed, w…
-
CLINICAL_TRIALS trial_result · 2021-10-28Clinical Trial Update: BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) [Phase 2]
Phase 2 study of zanubrutinib (BGB-3111) in Chinese participants with Diffuse Large B-Cell Lymphoma (non-GCB) and indolent lymphomas (Follic…
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-10-19Clinical Trial Update: Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma [Phase 2]
Phase II trial update for dose-adjusted EPOCH-Rrituximab in adults with untreated Burkitt lymphoma and c-MYC positive diffuse large B-cell l…